- Alnylam Pharmaceuticals (NASDAQ:ALNY -5.7%) Q1 results: Revenues: $33.3M (+52.1%); ONPATTRO: $26.3M; Net revenues from collaborators: $7M.
- Net Loss: ($181.9M) (-28.8%); Loss Per Share: ($1.73) (-22.7%); Non-GAAP Net Loss: ($149.9M) (-23.3%); Non-GAAP Loss Per Share: ($1.42) (-16.4%).
- 2019 Guidance: R&D expenses: $550M - 590M from $520M - 560M; SG&A expenses: $390M - 410M from $390M - 420M.
- Previously: Alnylam Pharmaceuticals beats by $0.38, beats on revenue (May 1)
Alnylam Q1 ONPATTRO sales $26.3M
Recommended For You
More Trending News
About ALNY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALNY | - | - |
Alnylam Pharmaceuticals, Inc. |